Humana Inc.

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +50

UnitedHealth and Humana Soar in April: Which Healthcare Stock Is Winning and Why

AI-generated analysis

📈 UnitedHealth stock surged 36% since March while Humana gained 34%, with UNH leading the sector on price and fundamentals.

💰 UnitedHealth beat Q1 2026 earnings estimates with adjusted EPS of $7.23 versus $6.57 consensus and revenue of $111.72 billion.

📉 Humana stock is recovering from a steep drawdown following Q4 2025 results that lowered FY2026 guidance to at least $9 due to Star Ratings headwinds.

🏥 UnitedHealth improved its medical cost ratio to 84% and raised its 2026 adjusted EPS outlook to more than $18.25.

👥 Humana achieved roughly 25% growth in individual Medicare Advantage membership in 2026, with January additions of about 1,030,700 members.

🛡️ UnitedHealth's diversified Optum unit provides earnings stability that is less sensitive to Medicare Advantage rate notices compared to Humana.

⚖️ Humana faces higher concentration risk as its heavy reliance on Medicare Advantage exposes it to regulatory rate decisions and Star Ratings volatility.

📅 Humana is scheduled to report Q1 2026 results on April 29, with traders pricing a 76% probability of a beat based on management telegraphing 110% to 115% of full-year adjusted earnings.

🔮 Sector tailwinds include softer hospital volumes from peers and finalized 2% rate increases for 2027 Medicare Advantage payments benefiting both companies.

Bullish Signals
  • Humana stock rallied 4% in April to $233, reflecting a recovery from steep drawdowns linked to Q4 2025 earnings and stabilizing consumer-focused strategy.
  • Individual Medicare Advantage growth reached roughly 25% in 2026, with January membership increasing by approximately 1,030,700 members, validating the company's strategic pivot.
  • Polymarket traders are pricing a 76% probability that Humana will beat Q1 2026 earnings, supported by management guidance of 110% to 115% of full-year adjusted earnings for the quarter.
  • The broader managed care sector rebound is extending into April, with Humana participating in a group rally driven by softer hospital volumes and favorable rate environments.
Risk Factors
  • Humana remains heavily concentrated in Medicare Advantage, leaving its stock more exposed to regulatory rate decisions and Star Ratings volatility than diversified peers.
  • The company's Q4 2025 earnings report showed a sharp step-down in FY2026 guidance to at least $9, driven specifically by headwinds related to Star Ratings.
  • Humana faces regulatory risks regarding Medicare Advantage rates and potential drug pricing reform that could impact its core business model more severely than diversified competitors.
Full Analysis
UnitedHealth Group (UNH) and Humana (HUM) are leading a sector-wide rebound in April 2026, with both stocks rising approximately 4% to trade near $368 and $233 respectively. UnitedHealth has significantly outperformed Humana year-to-date, gaining 12% compared to Humana's decline of 9%, driven by strong fundamentals and a clear earnings beat in early April. UnitedHealth reported Q1 2026 adjusted EPS of $7.23 against a consensus of $6.57, with revenue reaching $111.72 billion versus an estimate of $109.57 billion. The company improved its medical cost ratio to 84% and raised its full-year 2026 adjusted EPS outlook to over $18.25 while maintaining revenue guidance above $439 billion, signaling robust operational efficiency. Humana's stock rally reflects a recovery from steep drawdowns linked to Q4 2025 earnings, which featured a sharp step-down in FY2026 guidance due to Star Ratings headwinds. However, the bullish case for Humana centers on individual Medicare Advantage growth of roughly 25% in 2026, with January membership increasing by approximately 1.03 million members. The article highlights a strategic divergence between the two giants: UnitedHealth benefits from its diversified Optum unit and lower exposure to Medicare Advantage rate volatility, whereas Humana remains heavily concentrated in Medicare Advantage, making it more sensitive to regulatory rate decisions and Star Ratings fluctuations.